Lexeo Therapeutics have shared the message below for our FA Community on their Friedreich ataxia program based on highlights from their first quarter 2026 results.
Lexeo Therapeutics SUNRISE-FA 2 Trial Update
Previous
Previous
Design Therapeutics RESTORE-FA Trial Update
Next
Next